0.00Open0.00Pre Close0 Volume0 Open Interest100.00Strike Price0.00Turnover276.38%IV-392.61%PremiumDec 20, 2024Expiry Date79.70Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9733Delta0.0072Gamma0.25Leverage Ratio-0.0128Theta-0.0186Rho-0.25Eff Leverage0.0032Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet